Legend Biotech (LEGN) Gains from Investment Securities (2020 - 2025)

Legend Biotech (LEGN) has reported Gains from Investment Securities for 6 consecutive years, with -$53000.0 the latest figure, recorded in Q2 2025.

• Quarterly Gains from Investment Securities fell 100.05% year-over-year to -$53000.0 in Q2 2025, while the trailing twelve-month figure through Sep 2025 was -$149.8 million (down 163.6% YoY) and the FY2023 annual result came in at $85.8 million, up 14560.37% from the prior year.
• Gains from Investment Securities slipped to -$53000.0 in Q2 2025 per LEGN's latest filing, from $53000.0 in the prior quarter.
• Over the last five years, Gains from Investment Securities for LEGN reached as high as $108.2 million in Q2 2024 and fell as low as -$149.8 million in Q4 2024.
• A 5-year average of $21.0 million and a median of $64500.0 in 2021 frame the typical range for Gains from Investment Securities.
• Annual changes were most pronounced in 2021 — Gains from Investment Securities tumbled 163900.0% — and 2024, when it soared 144314.67%.
• Year by year, Gains from Investment Securities stood at $50.1 million in 2021, then soared by 99.66% to $100.0 million in 2022, then dropped by 14.24% to $85.8 million in 2023, then slumped by 274.69% to -$149.8 million in 2024, then soared by 99.96% to -$53000.0 in 2025.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered -$53000.0, $53000.0, and -$149.8 million for Q2 2025, Q1 2025, and Q4 2024 respectively.